Biomedical subjects

M Elizabeth Halloran

Publications and source records attributed to M Elizabeth Halloran.

7 recordsLinked to original sources

PubMed2003

Effects of pertussis vaccination on disease: vaccine efficacy in reducing clinical severity.

We estimated the effectiveness of pertussis vaccination in reducing the clinical severity of breakthrough disease among vaccinated individuals from a comprehensive follow-up study of a community of 30,000 residents of Niakhar, Senegal, in 1993. A physician examined all children with potential pertussis (cough of >7 days' duration). Samples were collected from 97% of these children for culture or serologic testing as part of the active surveillance for a pertussis vaccine trial. Cases of pertussis were defined by confirmation through culture or serologic testing or by a history of contact with a person with culture-confirmed pertussis. Among children with confirmed cases, severity of illness was assessed according to a scale that combined clinical signs and symptoms. The efficacy of the vaccine in reducing disease severity was 48% (95% confidence interval, 39%-55%) among children vaccinated with 3 doses of whole-cell (67%) or acellular (32%) vaccine. Primary cases were more severe than secondary cases in residential compounds. Pertussis vaccination is effective in reducing the severity of illness.

Bordetella pertussis↗

PubMed2003

Estimating efficacy of trivalent, cold-adapted, influenza virus vaccine (CAIV-T) against influenza A (H1N1) and B using surveillance cultures.

The authors report on a community-based, nonrandomized, open-label study, conducted during the 2000-2001 influenza season in Temple-Belton, Texas, of the protective effectiveness of trivalent, cold-adapted, influenza virus vaccine (CAIV-T) in children aged 18 months-18 years. The dominant circulating strains in 2000-2001 were influenza A/New Caledonia/20/99 (H1N1) and influenza B/Sichuan/379/99. Children had access to CAIV-T during the 1998-1999, 1999-2000, and 2000-2001 influenza seasons. The vaccine included influenza A/Sydney/5/97 (H3N2) and B/Beijing/184/93-like (B/Ann Arbor/l/94) strains in all three seasons. The vaccine included A/Beijing/262/95 (H1N1) in 1998-1999 and 1999-2000, which was replaced by A/New Caledonia/20/99 (H1N1) in 2000-2001. When medically attended acute respiratory illness (MAARI) was used as the outcome, the protective effectiveness for children vaccinated in 2000 was 18% (95% confidence interval (CI): 11, 25). Based on a combination of a validation sample of surveillance cultures and the MAARI outcome, protective efficacy against combined influenza A (H1N1) and B was 79% (95% CI: 51, 91). The efficacy estimate, after accounting for missing influenza culture status, against influenza A (H1N1) alone was 92% (95% CI: 42, 99) and against a new variant of influenza B alone was 66% (95% CI: 9, 87). CAIV-T provides substantial protection against a mixture of influenza A (H1N1) and B. Results demonstrate the powerful potential of using validation sets for outcomes in vaccine field studies.

Adolescent↗

PubMed2003

Effects of pertussis vaccination on transmission: vaccine efficacy for infectiousness.

We estimated the effect of pertussis vaccination on reducing transmission from vaccinated breakthrough cases from a comprehensive follow-up of a community of 30,000 residents in Niakhar, Senegal. Using a wide spectrum of case definitions, vaccine efficacy was estimated as 1 - the ratio of secondary attack rates (SAR) in all households with cases during the calendar year 1993, a pertussis epidemic year. Vaccine efficacy for infectiousness (VEi) was 85% (95% confidence interval (CI), 46-95%) for children vaccinated with three doses of a whole-cell (WC; 94%) or an acellullar (6%) pertussis vaccine, with pertussis defined as a cough >/=21 days with paroxysms confirmed by culture, serology, or contact with a culture-confirmed person. It was high for all case definitions. Partial vaccination reduced infectiousness. Pertussis vaccination is highly effective in reducing transmission from vaccinated breakthrough cases.

Child↗

PubMed2002

Containing bioterrorist smallpox.

The need for a planned response to a deliberate introduction of smallpox has recently become urgent. We constructed a stochastic simulator of the spread of smallpox in structured communities to compare the effectiveness of mass vaccination versus targeted vaccination of close contacts of cases. Mass vaccination before smallpox introduction or immediately after the first cases was more effective than targeted vaccination in preventing and containing epidemics if there was no prior herd immunity (that is, no prior immunologic protection within the population). The effectiveness of postrelease targeted and mass vaccinations increased if we assumed that there was residual immunity in adults vaccinated before 1972, but the effectiveness of targeted vaccination increased more than that of mass vaccination. Under all scenarios, targeted vaccination prevented more cases per dose of vaccine than did mass vaccination. Although further research with larger-scale structured models is needed, our results suggest that increasing herd immunity, perhaps with a combination of preemptive voluntary vaccination and vaccination of first responders, could enhance the effectiveness of postattack intervention. It could also help targeted vaccination be more competitive with mass vaccination at both preventing and containing a deliberate introduction of smallpox.

Adolescent↗

PubMed2002

Community interventions and the epidemic prevention potential.

Evaluation of community-level effects of intervention programs in infectious diseases is receiving increased attention. In this paper, we consider evaluation of the community-level effectiveness measures on the example of vaccination of children against influenza. We introduce the concept of the epidemic prevention potential (EPP) as a measure of the ability of an intervention to either prevent transmission or at least to keep it below a pre-defined limit. As a concept to describe the general ability of an intervention to limit outbreaks to a certain defined size, the term EPP fills a void. We constructed a stochastic simulation model of influenza transmission and vaccination in a structured community to illustrate the effectiveness measures of interest and the epidemic prevention potential. The concepts are general and could be applied to other interventions, such as antivirals and quarantine.

Adult↗

PubMed2002

Model-based estimation of vaccine effects from community vaccine trials.

Community vaccine trials are becoming increasingly important to assess both the direct and indirect community level effects of vaccination. In this paper, we present statistical methods to analyse such trials, using a design with several matched pairs of communities. The communities are matched on similarities in infection transmission as reflected through the basic reproduction number. Two methods of analysis are presented and compared. The first is simple empirical estimation of vaccine effects. Summary measures of these effects are constructed by reciprocal variance weighted averages across the community pairs. The second is likelihood-based where we derive a mixed effects epidemic model. This model takes the intercommunity variability into account through a random effect on the basic reproduction number. With this model, we derive a distribution-free estimator for the variance of the random effect. We use simulated epidemics to explore the performance of the two estimation methods for different numbers of community pairs and different levels of inter-pair variability. Both methods provide acceptable estimates in terms of bias and precision under reasonable conditions. Although the empirical approach involves fewer assumptions than the model-based approach, the resulting vaccine effectiveness estimates are only applicable to the vaccination fraction tested in the trial. In contrast, the model-based approach can be used to predict the vaccine effectiveness at vaccination fractions other than those used in the trial. Thus, it can be used as a public health policy tool for predicting the community level effects of vaccination. We demonstrate such use by predicting total vaccine effectiveness for the whole range of vaccination fractions.

Computer Simulation↗

PubMed2002

Subtype-specific transmission probabilities for human immunodeficiency virus type 1 among injecting drug users in Bangkok, Thailand.

The Bangkok (Thailand) Metropolitan Administration cohort of injecting drug users (IDUs) consisted of 1,209 IDUs initially seronegative for human immunodeficiency virus (HIV) who were followed from 1995 to 1998 at 15 Administration drug treatment clinics. At enrollment and approximately every 4 months thereafter, participants were assessed for HIV seropositivity. As of December 1998, there were 133 HIV type 1 seroconversions and approximately 2,300 person-years of follow-up. Of the 133 observed seroconversions, specimens from 126 persons were available for subtyping (27 subtype B, 99 subtype E). In this analysis, the authors assessed differences in subtype-specific transmission while controlling for important risk factors. The methodology used accounts for left truncation, interval censoring, and competing risks as well as for time-varying covariates such as each IDU's history of reported frequency of injection and of incarceration. Using plausible epidemiologic assumptions and controlling for behavioral risks, the authors found that a significantly higher transmission probability was associated with subtype E compared with subtype B in this population. Since many epidemiologic, virologic, and host factors can influence HIV transmission, it was difficult to conclude whether these differences in transmission probabilities were due to biologic properties associated with subtype.

Adolescent↗